Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$237.65 USD

237.65
1,133,443

+1.43 (0.61%)

Updated Sep 12, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

by Zacks Equity Research

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

by Zacks Equity Research

QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop

by Zacks Equity Research

Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

by Zacks Equity Research

Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Here's Why Investors Should Buy ResMed (RMD) Stock Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

by Zacks Equity Research

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

by Zacks Equity Research

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Investors Should Hold Teladoc (TDOC) Stock Now

by Zacks Equity Research

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume

by Zacks Equity Research

GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.

Are Medical Stocks Lagging Artivion (AORT) This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Zacks.com featured highlights include General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive

by Zacks Equity Research

General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive are part of the Zacks Screen of the Week article.

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

by Zacks Equity Research

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

by Zacks Equity Research

Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.